Business Overview: NeoGenomics, Inc. (Nasdaq: NCI)

---

Executive Summary

NeoGenomics, Inc. is a Fort Myers, Florida-headquartered, pure-play oncology diagnostics company founded in 1995. It operates CAP-accredited, CLIA-certified laboratories across the U.S. (Fort Myers FL; Aliso Viejo and Carlsbad CA; Research Triangle Park NC; Houston TX) plus a CAP-accredited sample-processing lab in Cambridge, UK, running genomic, cytogenetic, flow cytometry, and molecular tests used to diagnose and monitor cancer.

NeoGenomics' stated mission — "to save lives by improving patient care" — reflects a business built around being the specialized, high-complexity testing partner that community pathology practices, hospital labs, academic centers, and pharmaceutical companies turn to when they lack in-house cancer-testing depth. With roughly $660.6 million of 2024 revenue growing double digits and a published test menu spanning cytogenetics to next-generation sequencing (NGS) to liquid biopsy, NeoGenomics has positioned itself as one of the few labs with genuinely national scale focused exclusively on cancer.

---

1. Core Business Model & How They Work

NeoGenomics earns revenue by running and interpreting specialized cancer tests ordered by physicians and pharmaceutical sponsors, billing payers, clients, or patients directly, rather than selling a product.

[ Physician/Pharma orders test ] ➡️ [ Specimen shipped to CAP/CLIA lab ] ➡️ [ Technical testing (cytogenetics, FISH, flow, NGS) ]
        ➡️ [ Pathologist/molecular expert interpretation ] ➡️ [ Report returned to ordering physician ] ➡️ [ Billed to payer, client, or pharma sponsor ]

Key Operational Drivers

1. Flexible Service Models: Clients can order technical-only (TC) testing and interpret results themselves, a professional-component (PC) interpretation of someone else's technical work, or a comprehensive service covering both — letting NeoGenomics serve everyone from large hospital systems with their own pathologists to small community practices with none.
2. Pharma Services: Beyond routine clinical testing, NeoGenomics supports drug sponsors with biomarker discovery, clinical-trial testing, and companion-diagnostic development (including FDA submission support) — embedding itself directly into drug-development pipelines.
3. Oncology Data Solutions: Licenses de-identified testing data to pharmaceutical and biotech companies, turning its growing specimen and results database into a second revenue stream.
4. Scale-Driven Reimbursement Mix: 2024 revenue was billed 72% to clients directly, 15% to commercial insurance, and 13% to Medicare/other government payers — a diversified base that limits exposure to any single payer's reimbursement policy.

---

2. Testing Platforms & Key Offerings

---

3. Competitive Landscape

NeoGenomics competes against both diversified national labs and narrowly focused, well-funded specialists.

                     ONCOLOGY-TESTING POSITIONING MATRIX
┌───────────────────────────────────────────────────────────────────┐
│ High                                                                │
│  ▲          [Guardant Health]  [Natera]        [NeoGenomics]       │
│  O          (liquid biopsy focus)               (broad oncology    │
│  N                                                menu, pure-play)  │
│  C                      [Exact Sciences]  [Caris Life Sciences]     │
│  O                                         [Tempus AI]               │
│  L          [Quest/Labcorp]                                         │
│  O          (broad, diversified lab menu)                           │
│  G Low                                                               │
│    └──────────────────────────────────────────────────────────────►│
│    Low      ONCOLOGY SPECIALIZATION / FOCUS                   High  │
└───────────────────────────────────────────────────────────────────┘

• Large national labs — Quest Diagnostics, Laboratory Corporation of America (Labcorp), and Bio-Reference Laboratories: far greater scale, name recognition, and client bases, but oncology is a small slice of a much broader diagnostics menu.
• Liquid-biopsy and large-panel specialists — Guardant Health, Natera, Exact Sciences, Caris Life Sciences, Tempus AI, and Myriad Genetics: narrower but deeply funded competitors pushing hard in the same high-growth liquid-biopsy and MRD-monitoring niches as RaDaR.
• Pharma services — competes with contract research organizations (CROs) and other clinical reference labs for biomarker and companion-diagnostic work.
• In-house capability — hospital pathology labs and physician in-office labs that choose to build rather than outsource testing.

---

4. Strategic Strengths & Risks

Strengths

• Pure-play oncology focus gives NeoGenomics a depth of cancer-specific test menu, pathologist expertise, and workflow design that generalist labs like Quest and Labcorp cannot easily match test-for-test.
• No customer concentration: no single client exceeded 10% of revenue in 2022, 2023, or 2024, limiting exposure to the loss of any one account.
• Multi-revenue-stream model: clinical testing, pharma services, and data licensing diversify growth drivers beyond simple test volume.
• Improving profitability trajectory: Adjusted EBITDA grew from $3.5 million (2023) to $39.6 million (2024) even as the GAAP net loss narrowed, evidence of operating leverage as volume scales.

Risks

• Continued GAAP net losses: a $78.7 million net loss in 2024 (narrowed from $88.0 million in 2023) shows the company is still not GAAP-profitable despite double-digit revenue growth.
• Reimbursement and payer pressure: with 28% of revenue from commercial insurance and Medicare/government combined, rate cuts or coverage changes are a direct earnings risk.
• Well-capitalized liquid-biopsy rivals: Guardant Health and Natera in particular are racing NeoGenomics' RaDaR platform in the fast-growing MRD/recurrence-monitoring category, a space where technology leadership can shift quickly.
• Capital intensity of genomic technology: staying current with NGS and liquid-biopsy platforms requires continuous lab and R&D investment that pressures margins.

---

5. Financial Overview

---

6. Summary Conclusion

NeoGenomics has built one of the few genuinely national, pure-play cancer-diagnostics businesses, combining a broad clinical test menu with a growing pharma-services and data-licensing franchise that generalist labs don't replicate and that gives it real embeddedness in biopharma drug development. The business is clearly scaling — Adjusted EBITDA improved more than tenfold in a single year — but it remains GAAP loss-making, and its forward trajectory depends on whether its RaDaR liquid-biopsy platform and NGS panels can keep pace with better-capitalized specialists like Guardant Health and Natera while reimbursement economics for cancer testing remain under pressure industry-wide.